PHARMACOGENOMICS OF MDR1 IN PATIENTS WITH CYSTIC FIBROSIS (CF)

囊性纤维化 (CF) 患者中 MDR1 的药物基因组学

• 批准号: 7368226
• 负责人: PAUL BERINGER
• 金额: $ 4.57万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7368226
• 关键词: PHARMACOGENOMICS; MDR1; PATIENTS; CYSTIC; FIBROSIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renal clearance of a number of compounds appears to be increased in patients with cystic fibrosis. In-vitro and animal data indicate that upregulation of P-glycoprotein within the renal tubules may account for the increased clearance in this population as a compensatory mechanism for the defect in the cystic fibrosis transmembrane regulatory gene (CFTR). The purpose of this study is to compare the pharmacokinetics of a P-gp probe, fexofenadine in patients with CF and age-matched control subjects. In addition, MDR1 genotype-phenotype relationships will be evaluated.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。囊性纤维化患者中许多化合物的肾脏清除率似乎有所增加。体外和动物数据表明，肾小管内 P-糖蛋白的上调可能是该人群清除率增加的原因，作为囊性纤维化跨膜调节基因 (CFTR) 缺陷的补偿机制。本研究的目的是比较 P-gp 探针非索非那定在 CF 患者和年龄匹配对照受试者中的药代动力学。此外，还将评估 MDR1 基因型-表型关系。